{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:23:18Z","timestamp":1791015798020,"version":"4.1.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Adv Skin Wound Care"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Dystrophic epidermolysis bullosa pruriginosa (DEB-Pr) is a rare subtype of dystrophic epidermolysis bullosa, and traditional treatments have limited efficacy. Dupilumab has demonstrated remarkable efficacy in relieving pruritus. In this case study, after traditional treatment failed, providers recommended the patient begin dupilumab to treat his pruritus. The patient was administrated a loading dose of 600 mg of dupilumab and a dose of 300 mg every 2 weeks. The Dermatology Life Quality Index and Pruritic Numeric Rating Scale were used to assess the patient\u2019s situation. After several months, the patient\u2019s DEB-Pr was considered in remission. Dupilumab may be a better choice than immunosuppressants for the treatment of pruritus in patients with DEB-Pr.<\/jats:p>","DOI":"10.1097\/asw.0000000000000096","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T20:00:24Z","timestamp":1705694424000},"page":"1-4","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Pruritus Anesis in Dystrophic Epidermolysis Bullosa Pruriginosa with Dupilumab"],"prefix":"10.1097","volume":"37","author":[{"given":"Dan-Yang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Wen","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"5","key":"bib1-20250615","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2133.1994.tb13109.x","article-title":"Epidermolysis bullosa pruriginosa: dystrophic epidermolysis bullosa with distinctive clinicopathological features","volume":"130","year":"1994","journal-title":"Br J Dermatol"},{"issue":"1","key":"bib2-20250615","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000245691","article-title":"Epidermolysis bullosa pruriginosa","volume":"195","year":"1997","journal-title":"Dermatology"},{"issue":"2","key":"bib3-20250615","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40257-015-0119-7","article-title":"Epidermolysis bullosa pruriginosa: a systematic review exploring genotype-phenotype correlation","volume":"16","year":"2015","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"bib4-20250615","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"bib5-20250615","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jaip.2021.11.034","article-title":"Dupilumab treatment reduces hospitalizations in adults with moderate-to-severe atopic dermatitis","volume":"10","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"bib6-20250615","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/12034754221130969","article-title":"Treatment with dupilumab in patients with atopic dermatitis: systematic review and meta-analysis","volume":"26","year":"2022","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"bib7-20250615","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1080\/09546634.2020.1853024","article-title":"Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response","volume":"33","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"bib8-20250615","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"bib9-20250615","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/all.15603","article-title":"Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances","volume":"78","year":"2023","journal-title":"Allergy"},{"issue":"2","key":"bib10-20250615","doi-asserted-by":"crossref","first-page":"AB312","DOI":"10.1016\/j.jaci.2021.12.002","article-title":"Dupilumab significantly reduces itch and hives in patients with chronic spontaneous urticaria: results from a phase 3 trial (LIBERTY-CSU CUPID study a)","volume":"149","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"bib11-20250615","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1525-1470.1999.99004.x","article-title":"Dystrophic epidermolysis bullosa associated with eosinophilic infiltrate and elevated serum IgE","volume":"16","year":"1999","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"bib12-20250615","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1399-0004.2006.00679.x","article-title":"Dystrophic epidermolysis bullosa pruriginosa in Italy: clinical and molecular characterization","volume":"70","year":"2006","journal-title":"Clin Genet"},{"key":"bib13-20250615","first-page":"2023-01-24","article-title":"Successful treatment of epidermolysis bullosa pruriginosa by dupilumab","year":"2023","journal-title":"J Dermatol"},{"issue":"1","key":"bib14-20250615","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/jdv.17671","article-title":"Dystrophic epidermolysis bullosa pruriginosa: a new case series of a rare phenotype unveils skewed TH2 immunity","volume":"36","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"bib15-20250615","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/bjd.18855","article-title":"Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab","volume":"182","year":"2020","journal-title":"Br J Dermatol"},{"issue":"1","key":"bib16-20250615","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000245691","article-title":"Epidermolysis bullosa pruriginosa","volume":"195","year":"1997","journal-title":"Dermatology"},{"issue":"2","key":"bib17-20250615","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nri.2017.118","article-title":"TH2 cell development and function","volume":"18","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"bib18-20250615","first-page":"520","article-title":"Successful treatment of epidermolysis bullosa pruriginosa with anti-IgE therapy (omalizumab): a case report and four years follow-up","volume":"11","year":"2020","journal-title":"J Clin Exp Dermatol Res"},{"issue":"4","key":"bib19-20250615","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/ajd.13342","article-title":"Epidermolysis bullosa pruriginosa successfully treated with concomitant topical and systemic agents","volume":"61","year":"2020","journal-title":"Australas J Dermatol"},{"issue":"1","key":"bib20-20250615","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/dth.12047","article-title":"Epidermolysis bullosa pruriginosa showing good response to low-dose thalidomide-a report of two cases","volume":"27","year":"2014","journal-title":"Dermatol Ther"}],"container-title":["Advances in Skin &amp; Wound Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ASW.0000000000000096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T21:00:22Z","timestamp":1750021222000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ASW.0000000000000096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/asw.0000000000000096","relation":{},"ISSN":["1538-8654","1527-7941"],"issn-type":[{"value":"1538-8654","type":"electronic"},{"value":"1527-7941","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}